Acquired resistance to PD-L1 inhibition can rewire the interferon-regulated secretory machinery in tumor cells, altering the ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

There is growing evidence that immune-positron emission tomography (immuno-PET) can provide a real-time quantitative readout ...

A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation ...

BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...

Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic ...

The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...

Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the brand ...

Source: Getty Images Avelumab plus axitinib did not improve overall survival in the overall population or in patients with PD-L1-positive disease. The median overall survival was 44.8 months in the ...

--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 IHC 28-8 pharmDx ...

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in ...